Gossamer Bio raises $120M via private placement of 16.6M shares at $7.21/share

Gossamer Bio, Inc.

Private placement of 16.6M shares at $7.21; gross proceeds ~$120M before expenses.
Participation by EcoR1 Capital, NEA, Weiss Asset Management, Rock Springs Capital, and others.
Proceeds to fund seralutinib R&D ahead of Phase 2 TORREY topline results in Q4 2022.
Expected close July 15, 2022; lock-up on shares until October 1, 2022.
Cash runway extended into mid-2024 with existing cash and debt facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.